[ ]   [ ]   [ ]                        [ ]      [ ]   [ ]

Russia - NoEnzLefttoSplit - Sep 29, 2022 - 11:56pm
 
Radio Paradise Comments - Steely_D - Sep 29, 2022 - 10:46pm
 
Radio Paradise NFL Pick'em Group - islander - Sep 29, 2022 - 9:36pm
 
Artificial Intelligence - Manbird - Sep 29, 2022 - 9:18pm
 
Wordle - daily game - NoEnzLefttoSplit - Sep 29, 2022 - 8:31pm
 
260,000 Posts in one thread? - GeneP59 - Sep 29, 2022 - 8:31pm
 
Can I use my ratings to create a playlist? - islander - Sep 29, 2022 - 6:35pm
 
Pink Floyd Set? - Steely_D - Sep 29, 2022 - 5:03pm
 
Name My Band - oldviolin - Sep 29, 2022 - 4:57pm
 
Things You Thought Today - GeneP59 - Sep 29, 2022 - 4:53pm
 
Two questions. That's it. I promise. - GeneP59 - Sep 29, 2022 - 4:26pm
 
Guns - R_P - Sep 29, 2022 - 2:36pm
 
Lowest rated song you gave a 10 - ScottFromWyoming - Sep 29, 2022 - 2:18pm
 
Recommended documentaries - haresfur - Sep 29, 2022 - 1:38pm
 
The Obituary Page - miamizsun - Sep 29, 2022 - 12:27pm
 
• • • The Once-a-Day • • •  - oldviolin - Sep 29, 2022 - 11:12am
 
Vinyl Only Spin List - kurtster - Sep 29, 2022 - 8:06am
 
What the hell OV? - oldviolin - Sep 29, 2022 - 7:57am
 
How's the weather? - Proclivities - Sep 29, 2022 - 7:10am
 
Bug Reports & Feature Requests - jarro - Sep 29, 2022 - 2:26am
 
Prog Rockers Anonymous - ianm42 - Sep 29, 2022 - 2:03am
 
They're made out of meat. - oldviolin - Sep 28, 2022 - 8:08pm
 
What Makes You Laugh? - ScottFromWyoming - Sep 28, 2022 - 8:06pm
 
Republican Party - Red_Dragon - Sep 28, 2022 - 6:50pm
 
Baseball, anyone? - Bill_J - Sep 28, 2022 - 5:34pm
 
NASA & other news from space - Red_Dragon - Sep 28, 2022 - 4:27pm
 
First Porcupine Tree Concert in Toronto - the_jake - Sep 28, 2022 - 12:21pm
 
Florida Hurricane preparedness - pilgrim - Sep 28, 2022 - 10:23am
 
The Abortion Wars - Red_Dragon - Sep 28, 2022 - 10:11am
 
Photography Forum - Your Own Photos - fractalv - Sep 28, 2022 - 8:56am
 
New RP Website! (2022) - eyke - Sep 28, 2022 - 8:47am
 
Derplahoma! - Red_Dragon - Sep 28, 2022 - 8:24am
 
Mixtape Culture Club - miamizsun - Sep 28, 2022 - 7:28am
 
Today in History - Red_Dragon - Sep 28, 2022 - 6:56am
 
Counting with Pictures - Proclivities - Sep 28, 2022 - 6:17am
 
What's the first concert you ever went to? - Coaxial - Sep 28, 2022 - 5:03am
 
TEXAS - Red_Dragon - Sep 27, 2022 - 6:34pm
 
Display Album Art/Hide Slideshow - Joril - Sep 27, 2022 - 12:58am
 
Blondie in Detroit - Red_Dragon - Sep 26, 2022 - 4:38pm
 
Bob Dylan - miamizsun - Sep 26, 2022 - 3:08pm
 
• • • BRING OUT YOUR DEAD • • •  - oldviolin - Sep 26, 2022 - 1:46pm
 
HALF A WORLD - oldviolin - Sep 26, 2022 - 1:39pm
 
Britain - R_P - Sep 26, 2022 - 11:57am
 
What the world needs now is .... - Red_Dragon - Sep 26, 2022 - 11:24am
 
China - miamizsun - Sep 26, 2022 - 7:28am
 
Really missing ABBA (not) - ColdMiser - Sep 26, 2022 - 6:59am
 
Joe Biden - VV - Sep 26, 2022 - 6:05am
 
Annoying stuff. not things that piss you off, just annoyi... - Red_Dragon - Sep 25, 2022 - 4:35pm
 
New App Changes. Can't Scroll Back On Comment Section of - Laptopdog - Sep 25, 2022 - 4:04pm
 
Art Show - Manbird - Sep 25, 2022 - 2:08pm
 
Italy - Red_Dragon - Sep 25, 2022 - 1:45pm
 
What are you listening to now? - eyke - Sep 25, 2022 - 12:45pm
 
Questions. - haresfur - Sep 25, 2022 - 12:24pm
 
Ambient Music - haresfur - Sep 25, 2022 - 12:16pm
 
Trump - westslope - Sep 25, 2022 - 11:30am
 
Judy Chops - gazweid - Sep 25, 2022 - 9:42am
 
Positive Thoughts and Prayer Requests - Red_Dragon - Sep 25, 2022 - 8:13am
 
Quick! I need a chicken... - haresfur - Sep 24, 2022 - 4:36pm
 
hey Siri, play radio paradise in the living room? - KurtfromLaQuinta - Sep 24, 2022 - 4:04pm
 
COVID-19 - nottheusualkind - Sep 23, 2022 - 9:38pm
 
Ukraine - Red_Dragon - Sep 23, 2022 - 9:16pm
 
RIP Barbara Billingsley - fateme.mollaei - Sep 23, 2022 - 6:40pm
 
YouTube: Music-Videos - thisbody - Sep 23, 2022 - 11:43am
 
Getting ads on Sonos Radio Paradise Plugin - scrubbrush - Sep 23, 2022 - 10:46am
 
Automotive Lust - KurtfromLaQuinta - Sep 23, 2022 - 6:14am
 
USA! USA! USA! - westslope - Sep 22, 2022 - 7:07pm
 
Pernicious Pious Proclivities Particularized Prodigiously - Red_Dragon - Sep 22, 2022 - 3:20pm
 
What makes you smile? - miamizsun - Sep 22, 2022 - 1:38pm
 
Climate Change - R_P - Sep 22, 2022 - 12:18pm
 
Sonos - scrubbrush - Sep 22, 2022 - 11:33am
 
Earthquake - Steely_D - Sep 22, 2022 - 9:40am
 
The Dragons' Roost - GeneP59 - Sep 22, 2022 - 6:55am
 
Anti-War - R_P - Sep 21, 2022 - 7:41pm
 
What is the meaning of this? - oldviolin - Sep 21, 2022 - 2:46pm
 
Grammar Police Rap Sheet - kbs - Sep 21, 2022 - 10:35am
 
Index » Radio Paradise/General » General Discussion » XPRIZE & Singularity University Page: 1, 2, 3  Next
Post to this Topic
miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 17, 2022 - 8:41am

didn't see an AI thread so this will have to do for now...




edit: full version


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: May 31, 2019 - 3:15pm


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Mar 12, 2019 - 6:12am

sort of the euro-version of singularity u 

Hello Tomorrow

We are a global non-profit on a mission to unlock the potential of deep technologies to solve the world's toughest challenges, by highlighting, empowering and connecting the most promising deeptech entrepreneurs across the globe with the right enablers.






black321

black321 Avatar

Location: An earth without maps
Gender: Male


Posted: Jan 25, 2019 - 9:59am



 miamizsun wrote:
busy day ahead, but i'd like to leave you with something good to snack on


 

I'll see your exponential tech, and raise you one big brother:

https://www.wired.com/story/is...
miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Jan 25, 2019 - 4:21am

busy day ahead, but i'd like to leave you with something good to snack on


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Sep 16, 2018 - 8:16am



an awesome display of people using technology to solve the biggest problems we have today (and in the future)  

this is much watch stuff (esp the energy presentation with ramez naam)

enjoy  










miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 21, 2018 - 3:48pm

Landmark FDA Approval Brings Powerful Gene Silencing Method to Market

Earlier this month, the FDA approved an entirely new family of drugs, one so powerful that it could put CRISPR-based gene therapy to shame. Backed by two decades of research and a Nobel Prize, these drugs have the ability to cure inherited diseases—and do so without actually needing to edit the delicate genome.

The green-lit therapy is patisiran, a drug ten years in the making by the Cambridge-based Alnylam for genetic nerve damage. But in this rare case, the nature of the drug is perhaps more significant: patisiran is based on a technology called RNA interference, or RNAi, which allows doctors to silence genes that aren’t properly functioning.

Patisiran is just the tip of the iceberg. In theory, RNAi has the potential to cure any disease caused by “bad” proteins, such as stroke, Alzheimer’s, high cholesterol, or other neurodegenerative disorders. The potential is so grand that scientists have long dubbed the technology a way to “drug the undruggable.”

“This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms,” said FDA commissioner Scott Gottlieb in a press release. “New technologies like RNA inhibitors, that alter the genetic drivers of a disease, have the potential to transform medicine, so we can better confront and even cure debilitating illnesses.”

With other RNA-based therapies hurtling down the drug development pipeline, it’s likely we’ll be seeing more of these drugs soon. Here’s what you need to know.
more


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 21, 2018 - 1:46pm

i'm fairly certain that anyone can sign up and livestream this summit

line up of speakers/presenters here

e
njoy
miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 17, 2018 - 6:33am

 islander wrote:

{#Ask}  

So when do we get to trial run the set?

 
when is now a good time?    {#Cheers}

miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 17, 2018 - 6:23am



Proclivities

Proclivities Avatar

Location: Paris of the Piedmont
Gender: Male


Posted: Aug 7, 2018 - 9:21am

 miamizsun wrote:

thanks! {#Wave}

i've been crazy busy with some "other" stuff

upgrading my solutions capability and whatnot

or at least that's how i'm trying to rationalize it

{#Biggrin}
 
Good to see you; your secret is safe.
spy smasher
islander

islander Avatar

Location: Seattle
Gender: Male


Posted: Aug 7, 2018 - 9:03am

 miamizsun wrote:

thanks! {#Wave}

i've been crazy busy with some "other" stuff

upgrading my solutions capability and whatnot

or at least that's how i'm trying to rationalize it

{#Biggrin}
 
{#Ask}  

So when do we get to trial run the set?


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 7, 2018 - 8:37am

 NoEnzLefttoSplit wrote:

Good to see you back J!

 

 
thanks! {#Wave}

i've been crazy busy with some "other" stuff

upgrading my solutions capability and whatnot

or at least that's how i'm trying to rationalize it

{#Biggrin}

NoEnzLefttoSplit

NoEnzLefttoSplit Avatar

Gender: Male


Posted: Aug 7, 2018 - 8:18am

 miamizsun wrote:
from last october (i think there's an updated version of this video)
 

 
Good to see you back J!

 
miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Aug 6, 2018 - 2:47pm

from last october (i think there's an updated version of this video)


 


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: May 22, 2018 - 4:12am

we need people with vision swinging for the fence...


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Apr 9, 2018 - 1:46pm


see more here
miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Jan 16, 2018 - 4:23am

Gene Therapy Had a Breakthrough 2017—2018 May Be Even Better

Gene therapy had a hell of a 2017. After decades of promises but failed deliveries, last year saw the field hitting a series of astonishing home runs.

The concept of gene therapy is elegant: like computer bugs, faulty letters in the human genome can be edited and replaced with healthy ones.

But despite early enthusiasm, the field has suffered one setback after another. At the turn of the century, the death of an 18-year-old patient with inherited liver disease after an experimental gene therapy treatment put the entire field into a deep freeze.

But no more. Last year marked the birth of gene therapy 2.0, in which the experimental dream finally became a clinical reality. Here’s how the tech grew into its explosive potential—and a sneak peek at what’s on the horizon for 2018.

1. Bad Blood, Meet CAR-T

It sounds like magic: you harvest a patient’s own immune cells, dose them with an injection of extra genetic material, and turn them into living cancer-hunting machines.

But in 2017, the FDA approved a double whammy of CAR-T immunotherapies. The first, green-lighted in August, helps kids and young adults battle an especially nasty form of leukemia called B-cell acute lymphoblastic leukemia. Two months later, a therapy for adults with non-Hodgkin lymphoma hit the scene.

Together, these approvals marked the long-anticipated debut of gene therapy in the US market. Previously, Europe has led the charge with its approval of Glybera in 2015, a gene therapy that reduces fatty acid buildup in the bloodstream.

The historic nod of confidence for CAR-T has already sparked widespread interest among academics and drug companies alike at finding new targets for the upgraded immune cells (the “T” in “CAR-T” stands for T-cell, a type of immune cell). CAR-T is especially exciting for the cancer field because it helps people who don’t respond to other classic treatments, such as chemotherapy.

Already in the works are treatments that target multiple myeloma, which causes multiple tumors in the bone or soft tissue, and glioblastoma, an aggressive brain tumor for which there is no cure.

But the technology’s potential is hardly limited to cancer. Last year, a preliminary study in two monkeys showed that genetically engineered stem cells can suppress and even eradicate HIV infections. The study, though small, tantalizingly suggests a whole new way to battle HIV after three decades of fruitless search for a vaccine. With multiple CAR-T therapies going through the pipeline, 2018 may very likely welcome new members onto the gene therapy scene.



more here...




miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Jan 11, 2018 - 9:26am

a new cancer xprize...{#Cheers}

The Future of Cancer Treatment Is Personalized and Collaborative

Just a few years ago, microscopes were the primary tool used in cancer diagnoses, but we’ve come a long way since.

“We still look at a microscope, we still look at what organ the cancer started in,” Wender said. “But increasingly we’re looking at the molecular signature. It’s not just the genomics, and it’s not just the genes. It’s also the cellular environment around that cancer. We’re now targeting our therapies to the mutations that are found in that particular cancer.”

Cancer treatments in the past have been largely reactionary, but they don’t need to be. Most cancer is genetic, which means that treatment can be preventative. This is one reason why newer cancer treatment techniques are searching for actionable targets in the specific gene before the cancer develops.

When asked how artificial intelligence and machine learning technologies are reshaping clinical trials, Wender acknowledged that how clinical trials have been run in the past won’t work moving forward.

“Our traditional ways of learning about cancer were by finding a particular cancer type and conducting a long clinical trial that took a number of years enrolling patients from around the country. That is not how we’re going to learn to treat individual patients in the future.”

Instead, Wender emphasized the need for gathering as much data as possible, and from as many individual patients as possible. This data should encompass clinical, pathological, and molecular data and should be gathered from a patient all the way through their final outcome. “Literally every person becomes a clinical trial of one,” Wender said.

For the best cancer treatment and diagnostics, Wender says the answer is to make the process collaborative by pulling in resources from organizations and companies that are both established and emerging.

It’s no surprise to hear that the best solutions come from pairing together uncommon partners to innovate.


miamizsun

miamizsun Avatar

Location: (3261.3 Miles SE of RP)
Gender: Male


Posted: Jan 9, 2018 - 6:43am

it's part of moving forward...

New Research Suggests Immunity to CRISPR Gene Editing Poses a Challenge

The issue arises in how the Cas9 proteins researchers use are manufactured.

The authors of the study noted that the most widely-used versions of the protein are extracted from the bacteria Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes). In bioengineering, particular bacteria—usually selected for being widely available and easy to cultivate—are often used to synthesize particular proteins. For example, most of our medical insulin is made from genetically modified E. coli. The researchers behind the study questioned whether because S. aureus and S. pyogenes regularly infect humans we might have built up some resistance to their proteins already. The infections they cause, often called strep and staph, are widespread enough that most people can be expected to have been exposed to the bacteria.

The study discovered that in many cases, human immune systems produced T-cells that specifically responded to the Cas9 protein from Staphylococcus aureus. This suggests that attempts at therapeutic use would cause an adaptive immune response that might render the therapy ineffective. Indeed, the authors of the paper wrote that use of these proteins in those who’ve been exposed to this bacteria could be harmful. “It may even result in significant toxicity to patients,” according to Stanford University’s Matthew Porteus, a  senior author of the paper. A paper by Wei Leong Chew suggests, “If left unchecked…it could lead to mortality.”

The authors of the paper wanted to ensure immune issues weren’t overlooked. “Like any new technology, you want to identify potential problems and engineer solutions for them,” according to Porteus. “And I think that’s where we’re at. This is an issue that should be addressed.”

But this is far from the end for CRISPR.


Page: 1, 2, 3  Next